The following drug products were reviewed and acted upon by the CDPHP Pharmacy and Therapeutics Committee on October 14, 2009.
Review the full CDPHP Clinical Formulary which includes tier status, prior authorization requirements and quantity limits for select drugs.
Also see Medicare Drug Formulary and Medicare Formulary Updates.
| Drug | New Tier / Formulary Status | Previous Tier / Formulary Status |
| Adcirca tablets (tadalafil) | 3, PA | New to market |
| Alagesic LQ oral solution (acetaminophen/butalbital/caffeine) | 3, E | New to market |
| Aplenzin extended-release tablets (bupropion) | 3, E | New to market |
| Asacol HD delayed-release tablets (mesalamine) | 2 | New to market |
| Atacand HCT tablets (candesartan cilexetil/hydrochlorothiazide) | 3 | 2 |
| Atacand tablets (candesartan cilexetil) | 3 | 2 |
| BenzaClin topical gel (clindamycin phosphate/benzoyl peroxide) | 3** | 2 |
| Besivance ophthalmic solution (besifloxacin) | 3 | New to market |
| bicalutamide tablets (generic for Casodex) | 1 | New to market |
| Casodex tablets (bicalutamide) | 3** | 2 |
| Catapres-TTS transdermal patch (clonidine) | 3** | 2 |
| Cetraxal otic solution (ciprofloxacin) | 3 | New to market |
| clindamycin phosphate/benzoyl peroxide topical gel (generic for BenzaClin) | 1 | New to market |
| clonidine TDS extended-release film, transdermal (generic for Catapres-TTS) | 1 | New to market |
| Coartem tablets (artemether/lumefantrine) | 3 | New to market |
| CombiPatch transdermal patch (estradiol/norethindrone acetate) | 3 | 2 |
| Cuprimine capsules (penicillamine) | 3 | 2 |
| Edluar sublingual tablets (zolpidem tartrate) | 3#, E | |
| Effient tablets (prasugrel) | 3 | New to market |
| Entocort EC enteric-coated granules in capsules (budesonide micronized) | 3 | 2 |
| Exforge HCT tablets (amlodipine/valsartan/hydrochlorothiazide) | 2 | New to market |
| Fanapt tablets (iloperidone) | 3,PA | New to market |
| Fosamax Plus D tablets (alendronate sodium/cholecalciferol) | 3 | 2 |
| Lamictal XR extended-release tablets (lamotrigine) | 3 | New to market |
| malathion topical lotion (generic for Ovide) | 1 | New to market |
| minocycline HCl extended-release tablets (generic for Solodyn) | 1, PA, E | New to market |
| Nucynta tablets (tapentadol) | 3, quantity limit of one 90-day course per 12 months | New to market |
| Nuvigil tablets (armodafinil) | 3, PA | New to market |
| Ovide topical lotion (malathion) | 3** | 2 |
| Rapaflo capsules (silodosin) | 3 | New to market |
| Renvela tablets (sevelamer carbonate) | 2 | New to market |
| risperidone orally disintegrating tablets (generic for Risperdal-M) | 1 | New to market |
| Samsca tablets (tolvaptan) | 3 | New to market |
| Sanctura XR extended-release capsules (trospium chloride) | 2, preferred | 3 |
| Simponi injection (golimumab) | 2, PA, SP | New to market |
| Synthetic conjugated estrogen cream | 3 | New to market |
| tacrolimus capsules (generic for Prograf) | 1 | New to market |
| Toprol-XL extended-release tablets (metoprolol succinate) | 3** | 2 |
| Treximet tablets (sumatriptan succinate/naproxen sodium) | 2, preferred* | 3* |
| Tri-Lo-Sprintec tablets (ethinyl estradiol/norgestimate generic for Ortho Tri-Cyclen Lo) | 1 | New to market |
| Ulesfia topical lotion (benzyl alcohol) | 3 | New to market |
| Urso and Urso Forte tablets (ursodiol) | 3** | 2 |
| ursodiol tablets (generic for Urso and Urso Forte) | 1 | New to market |
The drug names listed here are the registered and/or unregistered trademarks of third-party pharmaceutical companies unrelated to and unaffiliated with CDPHP. These trademarked brand names are included here for informational purposes only and are not intended to imply or suggest any affiliation between CDPHP and such third-party pharmaceutical companies.